- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia? ; volume:27 ; number:5 ; day:27 ; month:3 ; year:2013 ; pages:335-343 ; date:5.2013
CNS drugs ; 27, Heft 5 (27.3.2013), 335-343, 5.2013
- Urheber
-
Kucharska-Pietura, Katarzyna
Mortimer, Ann
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-013-0047-0
- URN
-
urn:nbn:de:101:1-2019090304575736910519
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kucharska-Pietura, Katarzyna
- Mortimer, Ann
- SpringerLink (Online service)
Ähnliche Objekte (12)
The interplay between vitamin D, exposure of anticholinergic antipsychotics and cognition in schizophrenia
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms?
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
Current antipsychotics
Atypical antipsychotics
The interplay between vitamin D, exposure of anticholinergic antipsychotics and cognition in schizophrenia
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms?
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
Current antipsychotics
Atypical antipsychotics
The interplay between vitamin D, exposure of anticholinergic antipsychotics and cognition in schizophrenia
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms?
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
Current antipsychotics